Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370008 | 0.82 | TLR7 (0.60) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5749046 | 0.82 | TLR7 (0.55) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5748604 | 0.82 | TLR7 (0.57) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5358343 | 0.81 | TLR7 (0.59) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5748398 | 0.81 | TLR7 (0.54) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL4565227 | 0.80 | TLR7 (0.51) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3885227 | 0.79 | TLR7 (0.66) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5745102 | 0.79 | TLR7 (0.52) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5747400 | 0.79 | TLR7 (0.52) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5749444 | 0.79 | TLR7 (0.52) | TLR7LMNAPOLBHRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188111-B2 | Amide and carbamate derivatives of alkyl substituted N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176821-A1 | Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4-Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl]Methanesulfonamides and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176821-A1 | Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4-Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl]Methanesulfonamides and Methods | IFNG, CCL11, IL4 | TLR7 273/4885LMNA 3624/4885POLB 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.